entertainment -WSS

entertainment

author：hotspot 2025-09-03 03:29:37 - browse：6172

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Why don't Americans have at

WSS

Akero's treatment for NASH falls short in cirrhosis study

Latigo launches with $135 million for Vertex

Nick Jonas talks about managing diabetes along with his career

Ebola vaccine can save some who are already sick, per new study

Bernie Sanders gets little from pharma CEOs on drug prices

Wellcome Trust names Røttingen as its new CEO

focus

entertainment

focus

At least 13 dead in Texas as scorching temps continue

Wellcome Trust names Røttingen as its new CEO

DIEP, the 'gold standard' of breast reconstruction, is under threat

Peter Marks talks Operation Warp Speed for Rare Diseases

State Dept. review finds Biden bears some blame for Afghanistan failures

Takeaways from AdvaMed, the largest medical devices conference

DIEP, the 'gold standard' of breast reconstruction, is under threat

Researchers CRISPR chickens in bid to protect them from bird flu

Novavax promises a turnaround & Lilly roils the obesity market

How doctors and nurses shape Google's AI

knowledge

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Abbott's new heart device gets FDA advisory panel nod

Readout Newsletter: Amylyx, Aurinia, and IQVIA

STAT Boddities: What happens to the brain when we get scared?

Wellcome Trust names Røttingen as its new CEO

Having children helps parents live longer, especially after age 80

focus

focus

hotspot

Wikipedia